母体抗HPA-1a抗体阻断整合素活化且阻断程度与FNAIT疾病严重度相关
本研究探讨胎儿/新生儿同种免疫性血小板减少症(FNAIT)中抗HPA-1a抗体对整合素αIIbβ3/αvβ3活化的影响。使用重组抗HPA-1a抗体及回顾性FNAIT样本(轻症与重症),发现抗体通过Fab段抑制整合素与配体结合及细胞黏附,且抑制程度与疾病严重度相关,为产前诊断和高危筛查提供依据。
要点
- 抗HPA-1a抗体通过Fab段阻断αIIbβ3/αvβ3与配体结合,不依赖Fc段。
- 整合素抑制程度与FNAIT疾病严重度相关,重症样本抑制更强。
- 强制整合素呈持续伸展构象可消除抗体介导的抑制。
核心结论
- 抗HPA-1a抗体可阻断整合素活化,可能强烈促进FNAIT疾病严重度。
研究设计与样本
- 使用重组抗HPA-1a抗体及与轻症或重症FNAIT相关的回顾性样本进行体外实验。
主要发现
- 抗HPA-1a抗体抑制αvβ3/αIIbβ3与玻连蛋白、纤连蛋白和纤维蛋白原结合并损害细胞黏附。
- 抑制呈抗体浓度依赖性,由Fab段介导且不需Fc尾。
- 整合素被强制为持续伸展构象时抑制被消除。
- 整合素抑制程度与FNAIT疾病严重度相关。
临床怎么用
- 结果可能有助于开发产前诊断试验,识别FNAIT及严重并发症高风险妊娠。
- 揭示β3整合素活化变构抑制的新机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a disorder caused by a mismatch in human platelet antigens (HPAs), leading to maternal antibody formation and platelet destruction in the fetus or neonate. The clinically most relevant antigen is HPA-1a on the β3 subunit of integrins αIIbβ3 and αvβ3, which are conformationally regulated cell adhesion receptors on platelets and endothelial cells and are crucial for hemostasis and vascular integrity. The clinical effects of anti-HPA-1a alloimmunization are highly heterogeneous and range from no symptoms to intracranial hemorrhage, potentially causing perinatal death or lifelong complications. However, determinants of disease severity are largely unknown, which hampers implementation of screening programs to identify alloimmunized high-risk women who may benefit from treatment. Using recombinant anti-HPA-1a antibodies and a retrospective cohort of FNAIT samples associated with mild or severe disease, we report that the tested anti-HPA-1a antibodies inhibit binding of integrins αvβ3/αIIbβ3 to their ligands (vitronectin, fibronectin, and fibrinogen) and impair cell adhesion. This inhibition is dependent on antibody concentration, is mediated by the antibody Fab region, and does not require the Fc tail, and is abolished when integrins are forced into a constitutively extended conformation. Furthermore, the extent of integrin inhibition correlates with disease severity. Together, our data demonstrate that anti-HPA-1a antibodies can block integrin activation, which likely contributes strongly to disease severity in FNAIT. These results may aid development of a prenatal diagnostic test to identify pregnancies at high risk of developing FNAIT and associated severe complications. In addition, these data reveal novel opportunities for allosteric inhibition of β3 integrin activation.
引用
- Stam W, Broekhuis JD, van der Meer FWT, et al. Maternal anti-HPA-1a antibodies block αIIbβ3/αvβ3 integrin activation, and blockade correlates with FNAIT disease severity. Blood. 2026. PMID: 41980042. doi:10.1182/blood.2025031683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。